Koru Life Science is a UK company that finds new uses for existing medicines and matches them to the patients most likely to benefit. We focus on rare and hard-to-treat diseases, where patients cannot wait for a decade of new-molecule discovery.
Koru Life Science is a UK research-led company. We draw on the UK's strengths in genomics, translational research and rare-disease communities, and partner internationally.
About us →We start from compounds that already have human safety data — approved, clinical-stage or shelved — and test them against new disease biology, shortening the road to patients.
Our repurposing approach →From the first experiment, we define who a treatment is for — using genetic and molecular markers to select the patients most likely to respond.
How we stratify →Human safety and pharmacology data already exist, removing much of the early risk that ends new-molecule programmes.
Programmes can move to patient studies sooner, which matters most for diseases that progress quickly.
Lower development cost makes small patient populations viable to serve.
Compounds discontinued for commercial or strategic reasons can find a second life in a new indication.
More than 7,000 rare diseases have been described, and most still have no approved treatment. Repurposing and patient stratification are among the most practical ways to change that.
Read about the Koru Rare Disease Initiative →people in the UK will be affected by a rare disease at some point in their lives.
Source: UK Rare Diseases Framework, DHSC (2021)
We'd like to hear from pharmaceutical companies, researchers, clinicians and patient organisations.